Key Highlights

  • BMEA shares rose 8.01% pre-market to $1.48, following Friday's 0.74% gain to $1.37.
  • The company completed enrollment of 64 participants across 18 clinical sites in the COVALENT-211 Phase II trial.
  • Topline 26-week primary endpoint data from COVALENT-211 is anticipated in the first quarter of 2027.
  • Earlier data from the COVALENT-111 trial showed a placebo-adjusted 1.5% mean HbA1c reduction at Week 52 in insulin-deficient patients.

Trial Milestone Drives Pre-Market Gains

Biomea Fusion, Inc. (NASDAQ:BMEA) shares rose in pre-market trading after the company announced completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II trial evaluating its lead candidate icovamenib in patients with insulin-deficient type 2 diabetes who remain inadequately controlled on standard-of-care therapies.

Biomea Fusion is a clinical-stage biopharmaceutical company headquartered in San Carlos, California, focused on the discovery and development of oral covalent small-molecule therapies for diabetes, obesity, and metabolic diseases. The company's lead candidate, icovamenib, is a covalent menin inhibitor designed to restore beta-cell function and provide durable glycemic control.

COVALENT-211 enrolled 64 participants across 18 clinical sites, randomized to receive either icovamenib or placebo for 12 weeks as an add-on to background therapy, followed by a 40-week off-treatment period to assess durability of glycemic control. The company anticipates reporting topline 26-week primary endpoint results in the first quarter of 2027, with a companion Phase II trial, COVALENT-212, expected to complete enrollment before year end.

Earlier Data Supports Continued Development

Biomea Fusion carries a market Capitalization of approximately $99.05 million. The company does not currently report a forward or trailing price-to-earnings ratio given its net loss position, with Earnings per share at negative $1.20. The stock's 52-week range spans $0.87 to $2.99.

The current trials build on findings from the earlier Phase II COVALENT-111 trial, which demonstrated durable and clinically meaningful reductions in HbA1c that persisted nine months after treatment completion. In patients with severe insulin-deficient type 2 diabetes, icovamenib achieved a placebo-adjusted 1.5% mean HbA1c reduction at Week 52, while a subgroup on GLP-1 receptor agonist-based therapy achieved up to a 1.8% placebo-adjusted reduction, with the drug generally well tolerated across all dosing arms.

Data Readout Remains Over a Year Away

Biomea Fusion's pre-market gain reflects investor optimism following the completion of a key enrollment milestone, even though the more consequential primary endpoint data remains more than a year away. Investors will likely continue tracking enrollment progress in the companion COVALENT-212 trial as the next near-term catalyst.